List of Dextenza drug patents
Dextenza is owned by Ocular Therapeutix.
Dextenza contains Dexamethasone.
Dextenza has a total of 4 drug patents out of which 0 drug patents have expired.
Dextenza was authorised for market use on 30 November, 2018.
Dextenza is available in insert;ophthalmic dosage forms.
Dextenza can be used as dextenza is approved for the treatment of ocular pain following ophthalmic surgery, treatment of ocular itching associated with allergic conjunctivitis; treatment of ocular inflammation and pain following ophthalmic surgery.
The generics of Dextenza are possible to be released after 16 November, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(1 year, 5 months from now) | |
| US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(6 years from now) | |
| US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(7 years from now) | |
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Oct 7, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
DEXTENZA family patents
16
United States
5
Australia
4
Canada
4
Japan
4
European Union
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic